Evidence map›Paper›PMID 29038234›Full record

Trial reportThe oncologist2018

Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study.

George A Fisher, Edward M Wolin, Nilani Liyanage, Susan Pitman Lowenthal, Beloo Mirakhur, Rodney F Pommier, Montaser Shaheen, Aaron Vinik, ELECT Study Group

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The oncologist, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Sex differences in carcinoid syndrome: A gap to be closed.Reviews in endocrine & metabolic disorders · 2022
    Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Quality of life in patients with midgut NET following peptide receptor radionuclide therapy.European journal of nuclear medicine and molecular imaging · 2019
    Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 2 countries.

George A FisherStanford University School of Medicine, Stanford, California, USA georgeaf@stanford.edu.
Edward M WolinMontefiore Einstein Center for Cancer Care, Bronx, New York, USA.
Nilani LiyanageIpsen, Les Ulis, France.
Susan Pitman LowenthalIpsen Biopharmaceuticals, Basking Ridge, New Jersey, USA.
Beloo MirakhurIpsen Biopharmaceuticals, Basking Ridge, New Jersey, USA.
Rodney F PommierOregon Health and Science University, Portland, Oregon, USA.
Montaser ShaheenUniversity of New Mexico Cancer Center, Albuquerque, New Mexico, USA.
Aaron VinikEastern Virginia Medical School, Norfolk, Virginia, USA.
ELECT Study Group
Ipsen (United States) · USEastern Virginia Medical School · USIpsen (France) · FRMontefiore Medical Center · USOregon Health & Science University · USStanford University · USUNM Comprehensive Cancer Center

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn the double-blind (DB) ELECT study, lanreotide depot/autogel significantly reduced versus placebo the need for short-acting octreotide for symptomatic carcinoid syndrome (CS) control in neuroendocrine tumor (NET) patients. Here we present patient-reported symptom data during DB and initial open-label (IOL) treatment. MATERIALS AND

methodsAdults with NETs and CS history, with/without prior somatostatin analog use, were randomized to 16 weeks' DB lanreotide 120 mg subcutaneous or placebo every 4 weeks, followed by 32 weeks' IOL lanreotide. Patients recorded diarrhea and/or flushing frequency and severity daily by Interactive Voice (Web) Response System for 1 month prior to randomization and throughout the study.

resultsOf 115 patients randomized (

conclusionImproved diarrhea and flushing control in CS patients during 16-week lanreotide treatment was sustained during maintenance of lanreotide treatment for the 32-week IOL phase (48 weeks total). IMPLICATIONS FOR PRACTICE: This study prospectively collected daily patient-reported data on diarrhea and flushing from the ELECT trial to evaluate the direct impact of lanreotide depot on patients' relief of carcinoid syndrome symptoms. Treatment with lanreotide depot was associated with significant reductions in the percentages of days patients reported symptoms of diarrhea and flushing, as well as reductions in the frequency and severity of daily symptoms compared with placebo during 16 weeks of double-blind treatment. These improvements were sustained for 32 additional weeks of open-label lanreotide treatment (i.e., through week 48 of treatment), resulting in clinically meaningful, long-term symptom reduction.

Indexed as

Antineoplastic AgentsDiarrheaDouble-Blind MethodFlushingFollow-Up StudiesGelsHumansNeuroendocrine TumorsPeptides, CyclicPrognosisProspective StudiesSomatostatinAntineoplastic AgentsGelslanreotidePeptides, CyclicSomatostatinCarcinoid syndromeClinical trialLanreotide depot/autogelNeuroendocrine tumorQuality of life

Identifiers

PMID29038234
PMCPMC5759819
OpenAlexW2766543874

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.